Evaluation of the Effect of Telmisartan (Micardis 80 mg/ MicardisPlus 80/12.5 mg; 80/25 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients.

Trial Profile

Evaluation of the Effect of Telmisartan (Micardis 80 mg/ MicardisPlus 80/12.5 mg; 80/25 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2014

At a glance

  • Drugs Telmisartan (Primary) ; Telmisartan/hydrochlorothiazide (Primary)
  • Indications Cardiovascular disorders; Hypertension
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 07 Apr 2011 Actual end date (1 Jan 2011) added as reported by ClinicalTrials.gov.
    • 07 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 May 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top